These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26668691)

  • 1. Hepatitis C genotype 4: The past, present, and future.
    Abdel-Ghaffar TY; Sira MM; El Naghi S
    World J Hepatol; 2015 Dec; 7(28):2792-810. PubMed ID: 26668691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.
    Papastergiou V; Karatapanis S
    World J Clin Cases; 2015 Mar; 3(3):210-20. PubMed ID: 25789294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials.
    Wendt A; Bourlière M
    Ther Adv Infect Dis; 2013 Dec; 1(6):191-208. PubMed ID: 25165553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease.
    Maan R; van der Meer AJ
    F1000Res; 2016; 5():. PubMed ID: 27006761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam.
    Nguyen HA; Cooke GS; Day JN; Flower B; Phuong LT; Hung TM; Dung NT; Khoa DB; Hung LM; Kestelyn E; Thwaites GE; Chau NVV; ; Turner HC
    Wellcome Open Res; 2019; 4():129. PubMed ID: 32734002
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
    de Bruijn W; Ibáñez C; Frisk P; Bak Pedersen H; Alkan A; Vella Bonanno P; Brkičić LS; Bucsics A; Dedet G; Eriksen J; Fadare JO; Fürst J; Gallego G; Godói IP; Guerra Júnior AA; Gürsöz H; Jan S; Jones J; Joppi R; Kerman S; Laius O; Madzikwa N; Magnússon E; Maticic M; Markovic-Pekovic V; Massele A; Ogunleye O; O'Leary A; Piessnegger J; Sermet C; Simoens S; Tiroyakgosi C; Truter I; Thyberg M; Tomekova K; Wladysiuk M; Vandoros S; Vural EH; Zara C; Godman B
    Front Pharmacol; 2016; 7():197. PubMed ID: 27516740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges.
    Shahnazarian V; Ramai D; Reddy M; Mohanty S
    Ann Gastroenterol; 2018; 31(5):541-551. PubMed ID: 30174390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel emerging treatments for hepatitis C infection: a fast-moving pipeline.
    Kardashian AA; Pockros PJ
    Therap Adv Gastroenterol; 2017 Feb; 10(2):277-282. PubMed ID: 28203284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.
    Leila ARS; Mousa MHA; Frakolaki E; Vassilaki N; Bartenschlager R; Zoidis G; Abdel-Halim M; Abadi AH
    ACS Omega; 2019 Jul; 4(7):11440-11454. PubMed ID: 31460249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COVID-19 Pandemic Affected Hepatitis C Virus Circulation and Genotypic Frequencies-Implications for Hepatitis C Prevention, Treatment and Research.
    Oliveira Correa JD; Chies JAB
    Epidemiologia (Basel); 2024 Apr; 5(2):160-166. PubMed ID: 38651388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on hepatitis C: Direct-acting antivirals.
    Seifert LL; Perumpail RB; Ahmed A
    World J Hepatol; 2015 Dec; 7(28):2829-33. PubMed ID: 26668694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
    Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of hepatitis C virus exposure in Egypt: Opportunities for prevention and evaluation.
    Miller FD; Elzalabany MS; Hassani S; Cuadros DF
    World J Hepatol; 2015 Dec; 7(28):2849-58. PubMed ID: 26668697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
    Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
    PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
    Saab S; Park SH; Mizokami M; Omata M; Mangia A; Eggleton E; Zhu Y; Knox SJ; Pang P; Subramanian M; Kowdley K; Afdhal NH
    Hepatology; 2016 Apr; 63(4):1112-9. PubMed ID: 26704693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
    Banerjee D; Reddy KR
    Aliment Pharmacol Ther; 2016 Mar; 43(6):674-96. PubMed ID: 26787287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
    Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P
    Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prospects for the treatment and prevention of hepatitis C in children.
    Ohmer S; Honegger J
    Curr Opin Pediatr; 2016 Feb; 28(1):93-100. PubMed ID: 26709684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.